Neuralstem in the News
NFL alumni take stance on front line of effort to treat brain injuries
Reporter Craig Wolff talks to former San Diego Charger Wayne Clark about Neuralstem’s and the National Football League Alumni Association’s new initiative to develop an NSI-189/traumatic brain injury trial for treating NFL alumni. “I’d be willing to participate in anything,” Clark said. “And I’d expect all of us, no matter our present condition, would do the same.”
NFL may test brain injury treatment on retired players
“When in doubt, sit it out.” CBS, reporting with AP, added to the Neuralstem-NFLAA NSI-189/TBI story citing the American Academy of Neurology researchers’ new guidelines that call for current athletes who have sustained a significant head injury during a game be removed from play.
NFL group, company teaming up for brain drug test
AP coverage of Neuralstem-National Football League Alumni Association initiative to develop a trial for treating NFL alumni members suffering from traumatic brain injuries with neurogenic NSI-189 was carried by numerous media outlets ranging from ABC News to The Washington Post.
NFL Alumni Back New Drug to Keep Brain-Injuries From “Destroying Quality of Life”
The NSI-189/TBI initiative by Neuralstem and the National Football League Alumni Association, to develop a trial to treat traumatic brain injury for former NFL players, is spotlighted.
Drug which could reverse depression symptoms draws interest of NFL Alumni Association
Lee Nystrom, Chairman of the Board, Emeritus of the NFL Alumni Association, which is headquartered in Newark, New Jersey, and Neuralstem’s CEO and President Richard Garr are quoted in this article about the new NFLAA-Neuralstem NSI-189/TBI initiative.
- Neuralstem, NFL Alumni Association To Test Feasibility Of Traumatic Brain Injury Treatment
- Football and Concussions: New Drug To Be Tested on NFL Alumni
- Michigan University Joins Lou Gehrig’s Clinical Trial
- Neuralstem Expands Lou Gehrig’s Disease Trials
- U-M May Recruit ALS Patients for Stem Cell Clinical Trial
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.